

## ELMMB Formulary Update

December / January 2019

Subscribe Now

And be one of the first to know...

**BLACK traffic Light** - not recommended for prescribing in primary or secondary care.

- **Liothyronine** – remains **BLACK** traffic light. An IFR application can be made in exceptional circumstances.
- **Padeliporfin** – untreated localised prostate cancer – not recommended by [NICE TA546](#)
- **Vandetanib** – medullary thyroid cancer – not recommended by [NICE TA550](#)

**RED traffic light** - Primary care prescribers should not be asked to prescribe (\*\* denotes NHS England Commissioned)

- **Amgevita** - Adalimumab biosimilar allocated to ELHE – 1<sup>st</sup> line choice in new patients.
- **Lenvatinib\*\*** – untreated advanced hepatocellular carcinoma – an option by [NICE TA551](#)
- **Liposomal cytarabine-daunorubicin** – untreated acute myeloid leukaemia – an option by [NICE TA552](#)
- **Gemtuzumab ozogamicin\*\*** – untreated acute myeloid leukaemia – as an option by [NICE TA545](#)
- **Pembrolizumab** – adjuvant treatment of resected melanoma with high risk of recurrence - an option by [NICE TA553](#) (Cancer Drugs Fund)
- **Espranor®** - buprenorphine oral lyophilisate – for use by Specialist Substance Misuse service **only**
- **Tofacitinib** – moderately severe active ulcerative colitis – an option by [NICE TA547](#)
- **Tisagenlecleucel** – relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years – an option by [NICE TA554](#) (Cancer Drugs Fund)
- **Free Style Libre** – **REMINDER** to prescribers that this is RED Traffic Light and patients should not be advised to go to their GP.

**GREEN Traffic Light** - may be prescribed by all prescribers within local or national recommendations

- **Flexitol® 25% Urea Heel Balm** – treatment of callus on heels and feet in diabetic patients
- **Flexitol® 10% Urea cream** – urea based emollient (replaces Eucerin [on formulary](#))
- **Space Chamber Plus®** – for use with MDIs (cost effective alternative)
- **Compact Space Chamber Plus®** – for use with MDIs (cost effective alternative)
- **Evacal D3** – Prevention & treatment of osteoporosis - cost-effective alternative to Adcal D3 in Primary Care
- **Budesonide Foam Enema** – 2<sup>nd</sup> line option where steroid preparation is required. (hydrocortisone foam enema currently in short supply)
- **Paravit-CF®** - when patients are initiated or switched to this product, prescribers should ensure that existing preparations for individual ingredients that included in Paravit-CF are discontinued.
- **Levonogestrel IUD (Levosert®)** 20mcg/24 hrs – intra-uterine Progesterone only contraceptive (licensed indications only)
- **Doxylamine succinate & pyridoxine hcl 10mg/10mg tablets (Xonvea®)** - nausea and vomiting of pregnancy in women who do not respond to conservative management
- **Semaglutide: Ozempic®** Insufficiently controlled Type 2 Diabetes.

## Guidelines/Other

- [Medicines Management Board Minutes](#)
- [Drug Safety Updates](#)
- [Nice Bites](#)
- [Prescribing Hot Topics](#)
- [Shared Care Guidelines](#)
- [New PrescQipp e-learning:](#)
  1. [Anticholinergic burden](#)
  2. [Reducing Opioid Prescribing in chronic pain](#)
- [Testosterone Shared Care Guideline](#)
- [Combined Adult and Child ADHD Shared Care Guideline](#)
- [Psoriasis – Biologic and High Cost Drug Pathway](#)
- [Lidocaine teething products – information for patients](#)
- [Training for Care Home Staff](#)
- [Nutritional Supplements in substance misusers – updated version](#)
- [Rifaximin prescribing guidance – updated](#)
- [Overactive Bladder Guideline - updated](#)
- [Gout Management Summary Guidelines – updated](#)
- [Hydroxychloroquine – Information for Prescribers](#)